Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Current Leases (2020 - 2025)

Historic Current Leases for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $837286.0.

  • SAB Biotherapeutics' Current Leases rose 11753.79% to $837286.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $837286.0, marking a year-over-year increase of 11753.79%. This contributed to the annual value of $393430.0 for FY2024, which is 4127.44% down from last year.
  • SAB Biotherapeutics' Current Leases amounted to $837286.0 in Q3 2025, which was up 11753.79% from $815064.0 recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Current Leases high stood at $1.2 million for Q3 2022, and its period low was $384892.0 during Q3 2024.
  • For the 5-year period, SAB Biotherapeutics' Current Leases averaged around $728636.1, with its median value being $607955.0 (2023).
  • As far as peak fluctuations go, SAB Biotherapeutics' Current Leases crashed by 5703.88% in 2022, and later soared by 11753.79% in 2025.
  • SAB Biotherapeutics' Current Leases (Quarter) stood at $1.1 million in 2021, then plummeted by 57.04% to $490794.0 in 2022, then skyrocketed by 36.5% to $669946.0 in 2023, then plummeted by 41.27% to $393430.0 in 2024, then skyrocketed by 112.82% to $837286.0 in 2025.
  • Its last three reported values are $837286.0 in Q3 2025, $815064.0 for Q2 2025, and $793360.0 during Q1 2025.